Alternatively, prostate cancer cells may have invoked mechanisms to bypass the cyclin D1 requirement (e.g. RB loss), thereby weakening the necessity to induce cyclin D1 accumulation (Lukas et al, 1995). This evidence concerns the gene CCND1 and prostate carcinoma.